Proceedings · Session S-484 · filed November 18, 2026

Translational ScienceSession paper

Neladalkib Wins Accelerated Approval: 49% ORR After Alectinib

FDA accelerated approval for neladalkib rests on a 222-patient single-arm ALKOVE-1 analysis: 49% ORR after alectinib, 32% after multiple TKIs, 5% permanent discontinuation.

By Tom Whitfield4 min read786 words

Summary

  • FDA granted accelerated approval to neladalkib (Nelkarmi) on November 17, 2026, 10 days ahead of the November 27 target action date.
  • ALKOVE-1 primary analysis covered 222 previously treated patients: 49% confirmed ORR (33 of 67) after alectinib only, 32% (50 of 155) after 2+ ALK TKIs plus chemotherapy.
  • Intracranial response rates were 55% versus 26% between the alectinib-only and heavily pretreated groups; 12-month response durability reached 52% and 51%.
  • Permanent discontinuation due to adverse reactions occurred in 5% of patients; adverse reactions in at least 20% included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, fatigue.
  • Nelkarmi and July-approved Jideytro reached GSK through its $10.6 billion Nuvalent acquisition, announced June 9, 2026.
<![CDATA[Neladalkib Accelerated Approval: What ALK Drug Developers Should Know]]>
Figure<![CDATA[Neladalkib Accelerated Approval: What ALK Drug Developers Should Know]]> — ckstockphoto / pixabay

A 222-patient single-arm trial with a 49% confirmed response rate carried GSK's neladalkib to FDA accelerated approval on November 17, 2026, 10 days ahead of the agency's original November 27 target action date.

The indication covers adults with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) who previously received alectinib as their only ALK tyrosine kinase inhibitor (TKI), or who received two or more prior ALK TKIs plus platinum-based chemotherapy. The product, branded Nelkarmi, holds Breakthrough Therapy and Orphan Drug designations.

What do the ALKOVE-1 numbers actually show?

The approval rests on ALKOVE-1 (NCT05384626), a global, single-arm phase 1/2 trial whose primary efficacy analysis included 222 previously treated patients.

  • Alectinib-only patients: confirmed overall response rate 49% (33 of 67); 76% of responders kept response for at least 6 months, 52% for at least 12 months.
  • Patients with 2+ prior ALK TKIs plus chemotherapy: response rate 32% (50 of 155); 69% of responders reached 6 months, 51% reached 12 months.
  • Intracranial response in patients with measurable brain metastases at baseline: 55% in the alectinib-only group versus 26% in the more heavily pretreated group.
  • Complete responses accounted for 25% and 11% of those two groups respectively.

The safety profile, in the same label:

  • Most common adverse reactions in at least 20% of patients: hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, fatigue.
  • Permanent discontinuation because of adverse reactions: 5%, most often hepatotoxicity.

These figures carry the evidentiary weight, and they come with limits worth naming. A 67-patient cohort inside a 222-patient single-arm trial estimates response without the randomized comparator that separates drug effect from disease trajectory, and the two intracranial response rates describe different patient populations rather than one head-to-head comparison.

"Patients with ALK-positive lung cancer are often treated with multiple targeted therapies over many years. Advances in treatment have brought us closer to the goal of managing ALK-positive lung cancer as a chronic condition, but balancing disease control and long-term tolerability remains a significant challenge. The approval of neladalkib provides an important new treatment option for patients," said Alice Shaw, MD, PhD, an ALKOVE-1 trial investigator and chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

How was the molecule engineered around earlier ALK inhibitors?

Neladalkib is a macrocyclic small molecule built with minimal bulk in the kinase's solvent-front region — the site where the G1202R mutation, the most common resistance mutation after second-generation ALK TKI therapy, is thought to block binding of earlier inhibitors. The structural work traces to Lin JJ and colleagues, published in 2024 in Cancer Discovery under the compound code NVL-655.

Two design decisions target known liabilities of the class. Lorlatinib's neurologic effects have been attributed to inhibition of tropomyosin receptor kinase (TRK); to spare TRK, developers added an N-ethylpyrazole group that clashes with a larger tyrosine residue found in TRK but not in ALK. A smaller topological polar surface area than lorlatinib — 84 Ų versus 110 Ų — also predicted favorable brain penetrance.

Those are structural and modeling arguments rather than clinical outcome measurements, and the label data include no randomized comparison against lorlatinib.

What changes for developers and portfolio managers?

Nelkarmi and Jideytro (zidesamtinib), approved in July for previously treated ROS1-positive NSCLC, both reached GSK through its $10.6 billion acquisition of Nuvalent, announced June 9, 2026. GSK's stated strategy — engineering new kinase inhibitors around the documented failure modes of earlier drugs in the same class — runs consistently across both assets.

"Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non–small cell lung cancer through its broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity. ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important, and we are pleased to bring this innovation to patients in the US," said Tony Wood, chief scientific officer at GSK.

The vendor claims deserve as much scrutiny as the trial numbers. GSK describes treatment courses that can last for years, and a therapy patients may take for years demands sustained, predictable commercial supply. Follow-on development is already running: the company is evaluating neladalkib in other solid tumors and in ALKAZAR, an ongoing phase 3 trial in TKI-naive ALK-positive NSCLC.

For R&D managers, the watchpoint sits in ALKAZAR and the expanded solid-tumor studies, where the single-arm 49% and 32% response rates either hold under a more rigorous design or they do not.

via pharmtech.com (Source)

Filed under

  • neladalkib
  • alk-positive-nsclc
  • fda-accelerated-approval
  • kinase-inhibitor-resistance
  • gsk
Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Senior reporter covering technology and product news in research and development at Hypothesis Wire.

268 articles

References

  1. Cancer Cell publishes sac-TMT plus osimertinib translational data
  2. Cancer Vaccine Beats Survival Endpoint, But Patent Clock Looms
  3. Merck Pays $400M Upfront for Preclinical KRAS G12D Glue in $2.13B Deal
  4. FDA Approves Pimicotinib for TGCT on 56% Response Rate
  5. FDA Clears Two AstraZeneca Biologics in Four Days

« Previous articleNext article »